For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans

Dealmaking, whether partnering or acquiring, is on the mind of Christi Shaw, the new CEO of Gilead's Kite. "Really we have one or two competitors," she told BioPharma Dive. "All of these other ones want us to buy them."